BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 37191843)

  • 21. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global patterns and trends in colorectal cancer incidence and mortality.
    Arnold M; Sierra MS; Laversanne M; Soerjomataram I; Jemal A; Bray F
    Gut; 2017 Apr; 66(4):683-691. PubMed ID: 26818619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
    Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
    JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
    Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
    BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
    Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
    Tran B; Kopetz S; Tie J; Gibbs P; Jiang ZQ; Lieu CH; Agarwal A; Maru DM; Sieber O; Desai J
    Cancer; 2011 Oct; 117(20):4623-32. PubMed ID: 21456008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
    Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
    Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The chromosomal instability pathway in colon cancer.
    Pino MS; Chung DC
    Gastroenterology; 2010 Jun; 138(6):2059-72. PubMed ID: 20420946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic and epigenetic instability in colorectal cancer pathogenesis.
    Grady WM; Carethers JM
    Gastroenterology; 2008 Oct; 135(4):1079-99. PubMed ID: 18773902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
    Lièvre A; Bachet JB; Boige V; Cayre A; Le Corre D; Buc E; Ychou M; Bouché O; Landi B; Louvet C; André T; Bibeau F; Diebold MD; Rougier P; Ducreux M; Tomasic G; Emile JF; Penault-Llorca F; Laurent-Puig P
    J Clin Oncol; 2008 Jan; 26(3):374-9. PubMed ID: 18202412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
    Lièvre A; Bachet JB; Le Corre D; Boige V; Landi B; Emile JF; Côté JF; Tomasic G; Penna C; Ducreux M; Rougier P; Penault-Llorca F; Laurent-Puig P
    Cancer Res; 2006 Apr; 66(8):3992-5. PubMed ID: 16618717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations during colorectal-tumor development.
    Vogelstein B; Fearon ER; Hamilton SR; Kern SE; Preisinger AC; Leppert M; Nakamura Y; White R; Smits AM; Bos JL
    N Engl J Med; 1988 Sep; 319(9):525-32. PubMed ID: 2841597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers.
    Kunt N; Araz M; Yildirim MS; Findik S; Kocak MZ; Eryilmaz MK; Artac M
    J Gastrointest Cancer; 2023 Dec; 54(4):1316-1321. PubMed ID: 37191843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [K-ras mutational status and tumour-infiltrating lymphocytes in human colon cancer: state of the art and future perspectives].
    Kocián P; Sedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Spíšek R; Fialová A
    Rozhl Chir; 2012 Aug; 91(8):427-32. PubMed ID: 23153426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.